BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 23292539)

  • 1. Deletion of WT1 and WIT1 genes and loss of heterozygosity on chromosome 11p in Wilms tumors in Japan.
    Kaneko Y; Takeda O; Homma C; Maseki N; Miyoshi H; Tsunematsu Y; Williams BG; Saunders GF; Sakurai M
    Jpn J Cancer Res; 1993 Jun; 84(6):616-24. PubMed ID: 8393432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
    Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
    Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation Potential of Hypodifferentiated Subsets of Nephrogenic Rests and Its Relationship to Prognosis in Wilms Tumor.
    Liu M; Lu J; Yu C; Zhao J; Wang L; Hu Y; Chen L; Han R; Liu Y; Sun M; Wei G; Wu S
    Fetal Pediatr Pathol; 2024; 43(2):123-139. PubMed ID: 38217324
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors.
    Walz AL; Ooms A; Gadd S; Gerhard DS; Smith MA; Guidry Auvil JM; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Bowlby R; Brooks D; Ma Y; Mungall AJ; Moore RA; Schein J; Marra MA; Huff V; Dome JS; Chi YY; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Jafari N; Ross N; Gastier-Foster JM; Perlman EJ
    Cancer Cell; 2015 Feb; 27(2):286-97. PubMed ID: 25670082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor.
    Green DM
    J Clin Oncol; 2020 Mar; 38(7):772-773. PubMed ID: 31951492
    [No Abstract]   [Full Text] [Related]  

  • 6. Loss of heterozygosity for chromosomes 16q in Wilms tumors predicts outcomes: A meta-analysis.
    Song YH; Li WL; Yang Z; Gao Y; Feng ZP
    World J Gastrointest Oncol; 2024 May; 16(5):2159-2167. PubMed ID: 38764827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glypican-3 mRNA expression level in Wilms tumor: correlation with histological type, stage, and outcome.
    Wari MN; Vallonthaiel AG; Ahmed A; Saxena D; Iyer VK; Mathur SR; Agarwala S; Bakhshi S; Srinivas V; Chattopadhyaya P; Sharma A; Gupta SD; Dinda A
    Pediatr Surg Int; 2017 Jun; 33(6):695-703. PubMed ID: 28432433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation frequencies in Wilms' tumor: A meta-analysis and systematic review.
    Deng C; Dai R; Li X; Liu F
    Cancer Sci; 2016 May; 107(5):690-9. PubMed ID: 26892980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of heterozygosity mapping in Wilms tumor indicates the involvement of three distinct regions and a limited role for nondisjunction or mitotic recombination.
    Coppes MJ; Bonetta L; Huang A; Hoban P; Chilton-MacNeill S; Campbell CE; Weksberg R; Yeger H; Reeve AE; Williams BR
    Genes Chromosomes Cancer; 1992 Nov; 5(4):326-34. PubMed ID: 1283321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms tumor genes.
    Huff V; Saunders GF
    Biochim Biophys Acta; 1993 Dec; 1155(3):295-306. PubMed ID: 8268188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of heterozygosity at 11p13 and 11p15 in Wilms tumor: a study of 22 cases from India.
    Sigamani E; Wari MN; Iyer VK; Agarwala S; Sharma A; Bakhshi S; Dinda A
    Pediatr Surg Int; 2013 Mar; 29(3):223-7. PubMed ID: 23292539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
    Charles AK; Brown KW; Berry PJ
    Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
    Grundy P; Telzerow P; Moksness J; Breslow NE
    Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
    Brown KW; Power F; Moore B; Charles AK; Malik KT
    Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High frequency of loss of heterozygosity for 1p35-p36 (D1S247) in Wilms tumor.
    Steinberg R; Freud E; Zer M; Ziperman I; Goshen Y; Ash S; Stein J; Zaizov R; Avigad S
    Cancer Genet Cytogenet; 2000 Mar; 117(2):136-9. PubMed ID: 10704684
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.